Introduction
Although bladder cancer is the fifth most common cancer in USA (1), the molecular mechanisms that determine neoplastic transformation in the bladder urothelium are still unknown. No specific or exclusive cytogenetic aberration has been identified for urothelial carcinoma (UC), but numerous non-random deletions, gain of chromosomes, polyploidization and formation of isochromosomes have been linked to it (2) .
In 1999, we identified the FEZ1/LZTS1 (LZTS1) tumor suppressor gene on chromosome 8p22 (3) . Subsequently, we demonstrated that the LZTS1 expression is often altered in human cancers with diverse histogenetic backgrounds, including those derived from prostate, breast, esophagous and stomach (3) (4) (5) . Furthermore, LZTS1expression was absent or reduced in oral squamous cell (6) and in lung carcinomas (5) , and, in the latter case, loss of LZTS1 expression was significantly associated with poor tumor grade and a higher mortality rate (7) .
The LZTS1 gene encodes a 67 kDa leucine zipper protein, which shares homology with the cyclic adenosine 3#,5#-monophosphateresponsive binding protein (3) and acts as a regulator of cell growth as well as an inhibitor of tumorigenesis (8) (9) (10) . The reintroduction of LZTS1 into LZTS1 null cancer cells suppresses cell growth, through a direct interaction between LZTS1 and the main mitotic kinase, p34 cdc2 (at present referred as Cdk1) (8) (9) (10) . Overexpression of LZTS1 protein induced a block of the cell cycle at late S-G 2 /M phase (8) (9) (10) . Conversely, inhibition of LZTS1 expression stimulated cell growth (8, 11) .
Notably, LZTS1 protein is reduced or absent in the majority of bladder cancer cell lines and primary UC samples tested (10) . Restoration of protein expression in a bladder tumor cell line inhibits cell growth, alters cell cycle progression and suppresses tumorigenicity in nude mice (10) . In agreement with these findings, a mutational analysis study of 54 bladder tumor samples and 34 bladder cancer cell lines discovered one new mutation (G374S) in one bladder cancer cell line and 42% of loss of heterozygosity in the 8p22 region of the tumor samples (12) . In addition, it was observed a marked reduction in LZTS1 messenger RNA levels in the majority of bladder cancer cell lines (12) .
Treatment of mice with N-butyl-N-(4-hydroxybutil) nitrosamine (BBN) results in the development of urinary bladder cancer that bears significant histopathological and molecular similarities to the human disease (13) . For this reason, this model has been previously used to characterize the tumorigenic process of urinary bladder cancer (14) . In the present study, we assessed the carcinogenic potential of BBN in Lzts1 knock-down mice to gain insight into the potential function of Lzts1 in vivo. We discovered that loss of one or both Lzts1 alleles favored development of bladder cancer induced by a classical carcinogen. Thus, LZTS1 may be an important target gene for therapeutic intervention and boosting its expression by pharmacological or gene therapy approaches might help combating bladder cancer in humans.
Materials and methods

Animal experiments
Animal experiments were conducted under institutional guidelines established for the Animal Facility at the Kimmel Cancer Center (Thomas Jefferson University, Philadelphia, PA). For the carcinogenicity study, 58 mice consisting of 25 Lzts1 þ/þ (13 males and 12 females), 17 Lzts1 þ/À (9 males and 8 females) and 16 Lzts1 À/À (8 males and 8 females) were treated with a freshly prepared solution of 0.1% BBN (TCI America, Portland, OR) in their drinking water, twice a week as described previously (14) . Mice were weighed, observed daily, and after 13 weeks of BBN treatment followed by 2 weeks of tap water, the mice were killed, and complete necropsy was conducted. At necropsy, all the bladders were first opened and checked for gross lesions and then fixed in 10% buffered formalin. To genotype the mice colony, DNA was isolated from mouse tail using the DNeasyÒ Tissue Kit (Qiagen, Valencia, CA). We designed a set of primers for the detection of the wild-type Lzts1 DNA and for the detection of the neomycin-resistant gene cassette used to generate the knock-out mice (9) (wild-type: forward primer 5#-CTGTGCAAAGCTGCAGTGAGG-3# and reverse primer 5#-ACTTCCGCTCTCACCAGTGCTGATC-3#; mutant: forward primer 5#-CTGTGCAAAGCTGCAGTGAGG-3# and reverse primer 5#-CGCTATCAGGACATAGCGTTGGCTACC-3#). Polymerase chain reaction (PCR) was performed using the PCR Core Kit (Roche, Mannheim, Germany). Each mixtures contained 18.50 ll of Nuclease-free water (Fisher Scientific, Fair Lawn, NJ), 2.5 ll of PCR reaction buffer, 0.75 ll of deoxynucleoside triphosphate mix, 1 ll each primer and 0.25 ll of Taq DNA polymerase in a total volume of 25 ll. PCR was performed at 94°C for 5 min to activate the Taq DNA polymerase, followed by 32 cycles at 94°C for 30 s, 65°C for 30 s and 72°C for 2 min. The PCR products were electrophoresed on 1.5% agarose gel and visualized after staining the gel with ethidium bromide (Figure 1 ).
Histologic and statistical analysis
The whole bladder was histologically examined through the evaluation of multiple 50 lm progressive sections. Histologic urothelial lesions were classified into four categories (Table I, Figure 2 ) as described previously (14) follows: (i) simple hyperplasia and mild dysplasia; (ii) moderate and severe dysplasia; (iii) in situ carcinoma and (iv) invasive carcinoma. For each case, only the most severe lesions were considered in the statisitical analysis. Severe dysplasia and carcinoma in situ were grouped together. The slides were randomized so that the three pathologists (R.B., A.V. and R.V.I.) evaluating the slides did not know the nature of the treatment received by each animal. The association between Lzts1 genotype, presence of preneoplastic lesions and bladder tumors was evaluated via the v 2 test. Differences were considered statistically significant at P , 0.05. All the statistical evaluations were performed with STATA software (Stata Corporation, College Station, TX).
Results
As we reported previously (9) , our data confirmed the higher susceptibility of Lzts1-deficient mice to develop tumors under the effect of a carcinogen using heterozygous and nullizygous Lzts1-deficient mice in a chemically induced carcinogenesis model. In the Lzts1 þ/þ group (Table I) , simple hyperplasia and mild dysplasia were detected in 20 mice (80.0%), three mice (12.0%) showed moderate to severe dysplasia and only two mice (8.0%) presented neoplastic lesions (one with in situ carcinoma and the other with invasive carcinoma). On the contrary, 14 of 17 (82.3%) Lzts1 þ/À and 15 of 16 (93.8%) Lzts1 À/À mice harbored invasive carcinomas. Mild to moderate dysplasia was diagnosed in the remaining Lzts1 þ/À (3/17) and Lzts1 À/À (1/16) mice. Preneoplastic lesions in the urothelium adjacent to advanced tumors were frequently observed. In most cases, as described previously (13, 14) , we observed squamous differentiation of neoplastic lesions. Specifically, 11 of 14 tumors in the Lzts1 þ/À and 12 of 15 tumors in the Lzts1 À/À mice showed squamous features. Furthermore, cancer infiltrated the deeper muscle in 10 of 14 Lzts1 þ/À mice and 11 of 15 Lzts1 À/À mice, respectively. The remaining tumors invaded the superficial muscle in both Lzts1 þ/À and Lzts1 À/À mice. No significant histopathological differences were observed between wild-type and knock-out mice. When we used three outcome categories (Table I) , the global P comparing all three groups was 1.3E-13, underlying the differences of outcomes across the genotypes. The pair-wise probabilities were as follows: wild-type versus heterozygous, P 5 1.4E-9; wild-type versus homozygous À/À , P 5 2.5E-14 and heterozygous versus homozygous À/À , P 5 NS.
Discussion
The short arm of chromosome 8 is frequently deleted in human cancers and its deletion is commonly associated with a more aggressive malignant phenotype (15, 16) . In previous studies, we have identified the LZTS1 gene on chromosome 8p22 (3), a region which showed loss of heterozygosity in invasive UC tumors (12, (17) (18) (19) , and shown that the LZTS1 protein is lost or decreased in most of the UC-derived cell lines and primary human urothelial bladder cancers analyzed (10). Moreover, there was a statistical association between decrease or absence of LZTS1 and high-grade bladder tumors. By restoring LZTS1 expression in SW780 bladder cancer-derived cells, we inhibited cell growth, altered cell cycle progression and suppressed tumorigenicity in immunocompromised mice (10) .
In a recent report, Knowles et al. (12) found a new mutation in A1698 bladder cancer cell line and 42% of loss of heterozygosity in the 8p22 region of a large series of bladder cancers. In the same study, a reduction in LZTS1 messenger RNA levels was also observed in the majority of bladder cancer cell lines (12) . All these data strongly suggest that LZTS1 is indeed involved in the progression of UC of the urinary bladder.
The exact mechanism whereby LZTS1 contributes to cancer initiation and progression is not known. Recent data suggest that LZTS1 is Fez1/Lzts1 and bladder cancer an important player in the execution of normal M-phase progression (9) . Moreover, the absence of Lzts1 leads to impaired chromosome segregation, cell transformation and cancer progression (9) . Transgenic mice, where Lzts1 has been knocked out in the germ line, have an increased incidence of both spontaneous and chemically induced cancers (9) . Since the LZTS1 gene is often downregulated in cancer (3) (4) (5) (6) (7) 10, 11) , and since BBN-induced bladder cancer is an established model to characterize the tumorigenic process for urinary bladder carcinogenesis (13, 14) , BBN treatment was used to determine whether Lzts1 modulates carcinogen-induced malignancy development. Treatment of mice with this carcinogen results in the development of transitional cell urinary bladder cancers with a high yield of tumor induction (13, 14) and high rate of squamous differentiation (.50% of the induced tumors) (13, 14, 20) . In this study, as in our previous experience (14) , we observed an almost complete squamous commitment of the neoplastic lesions. After 13 weeks of BBN administration, the majority of Lzts1-deficient mice (82.3% Lzts1 þ/À and 93.8% Lzts1 À/À ) developed invasive bladder cancers (Figure 2 ). These incidences were significantly higher than those observed in the group of wild-type mice. This confirmed our previous observation that Lzts1-deficient mice develop forestomach tumors more quickly after exposure to N-nitrosomethylbenzylamine (9), further suggesting that Lzts1 absence sensitizes multiple tissues to carcinogenesis. We also confirmed that there is no difference in the incidence of neoplastic lesions between heterozygous þ/À versus homozygous À/À mice (82.3 versus 93.8%). Thus, the loss of one single Lzts1 allele can predispose to bladder cancer formation. The difference in the incidence of bladder tumors between these mice is an important indication of the need for the urothelial cell to have both Lzts1 alleles intact to respond efficiently to the damaging action of a chemical carcinogen. Therefore, as observed for other tumor suppressor gene (21-23), we hypothesize that Lzts1 gene could be haploinsufficient in tumor suppression.
In conclusion, we have shown for the first time that Lzts1 null mouse is a useful and valid animal model for investigating the biology of bladder cancer. We further discovered that both Lzts1 alleles are necessary for a proper host response to chemical carcinogens such as BBN. Thus, further studies on this interesting gene are warranted to understand how Lzts1 participates in bladder carcinogenesis. Elucidation of the molecular mechanisms of LZTS1 activity might help not only the diagnosis but also the treatment of patients with this devastating disease.
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